Johnson & Johnson Acquires Firefly Bio for $1 Billion in Cash
Johnson & Johnson (JNJ) has agreed to acquire biotechnology company Firefly Bio for $1 billion in cash. The deal is expected to close later this year and aims to enhance J&J's capabilities through Firefly's proprietary degrader antibody conjugate platform.
Tickers: $JNJ